USP Issues Change to Viscosity Reference in Monographs
The United States Pharmacopeia has stated that references to General Chapter <911> "Viscosity" will be changed to General Chapter <911> "Viscosity-Capillary Viscometer Methods," <912> "Rotational Rheometer Methods," or <913> "Rolling Ball Viscometer Method."
The United States Pharmacopeia (USP) has stated that references to General Chapter <911> “Viscosity” will be changed to General Chapter <911> “Viscosity—Capillary Viscometer Methods,” <912> “Rotational Rheometer Methods,” or <913> “Rolling Ball Viscometer Method.” Seventy monographs will be affected.
The changes reflect a modernized General Chapter <911> and two new proposed General Chapters <912> and <913> published in Pharmacopeia Forum37(4) and 37(5) in 2011 and approved by the General Chapters—Physical Analysis Expert Committee.
The changes will become official Dec. 1, 2012, and will be reflected in the Second Supplement to USP 35–NF 30. A list of impacted monographs can be found on the USP website.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
